{"entity":{"id":"ct7439","kind":"drug","name":"CT7439","aka":[],"tldr":"CT7439 is an experimental pill from Carrick Therapeutics, in phase 1 trials for advanced solid tumours.","summary":"CT7439 is a small molecule, oral from Carrick Therapeutics. Blocks the enzymes CDK12 and CDK13 and acts as a molecular glue that breaks down cyclin K, which the company says weakens the cancer cell's repair of damaged DNA at the level of gene transcription. Its phase 1/2 study (NCT06600789) is recruiting people with solid tumours. CDK13 and cyclin K have no target record in OnCo. Whether it works in people has not been established.","status":"phase-1","asOf":"2026-11-04","links":[{"label":"Carrick Therapeutics CDK12/13 programme","url":"https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor"},{"label":"ClinicalTrials.gov NCT06600789","url":"https://clinicaltrials.gov/study/NCT06600789"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["cdk12"],"drugs":[],"companies":["carrick-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06600789"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors, investor portfolios (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-04"},"code":"CT7439","modality":"Small molecule, oral","mechanism":"Blocks the enzymes CDK12 and CDK13 and acts as a molecular glue that breaks down cyclin K, which the company says weakens the cancer cell's repair of damaged DNA at the level of gene transcription.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ct7439/","neighbours":{"target":[{"id":"cdk12","kind":"target","name":"CDK12","route":"/targets/cdk12/"}],"company":[{"id":"carrick-therapeutics","kind":"company","name":"Carrick Therapeutics","route":"/companies/carrick-therapeutics/"}],"trial":[{"id":"nct06600789","kind":"trial","name":"A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies","route":"/trials/nct06600789/"}]}}